Tranexamic acid (TXA) is an anti-fibrinolytic agent that inhibits fibrinolysis by blocking lysine binding sites on plasminogen. It is indicated for suspected severe traumatic hemorrhagic shock or following traumatic arrest if resuscitation is indicated. Contraindications include isolated head injury, hypersensitivity, history of thromboembolic disease, or current thromboembolic event. The dosage for traumatic injury is a 10 minute bolus followed by an 8 hour infusion, while traumatic arrest receives a single bolus. TXA must be initiated within 3 hours of injury and the receiving facility notified upon arrival.